Novel hyaluronan formulation for preventing acute skin reactions in breast during radiotherapy: a randomized clinical trial

Asal Rahimi, Osama Mohamad, Kevin Albuquerque, D. W.Nathan Kim, Diana Chen, Kimberly Thomas, Rachel Wooldridge, Aeisha Rivers, Marilyn Leitch, Roshni Rao, Barbara Haley, Chul Ahn, Dan Garwood, Ann Spangler

Research output: Contribution to journalArticle

Abstract

Purpose: We conducted a randomized, double-blind, vehicle-controlled clinical trial to investigate the use of a new proprietary hyaluronan (HA) formulation for the prevention of acute skin toxicity in breast cancer patients undergoing radiotherapy (RT). Methods: Thirty women with breast cancer undergoing whole breast RT were enrolled. Each patient was randomly assigned to HA formulation (study cream, S) on the medial or lateral half of the irradiated breast and the control cream (placebo, P) on the other half. The primary endpoint was physician’s evaluation of skin symptoms at week 5 during RT and week 2 post-RT. We also collected patients’ independent assessment of skin after RT, patient’s product preference, and an independent physician panel assessment of skin reactions based on photographs. Results: Twenty-eight patients were evaluable. On physician’s evaluation, there was no significant difference in radiation dermatitis between S and P and no overall preference to either cream at week 5 during or week 2 post-RT. More patients preferred S in evaluating skin appearance and skin reactions, but this did not reach statistical significance. Univariate analysis showed that physicians had an overall preference to the S cream at week 2 post-RT in patients with larger breasts. On the independent panel assessment, 3 reviewers saw no significant difference in radiation toxicity, whereas one reviewer reported better skin outcome with S cream at week 5. Conclusions: We found a nonstatistically significant patient preference but overall no significant radioprotective effects for this HA formulation compared with placebo except in patients with larger breasts. Trial registration: The study was registered at www.clinicaltrials.gov (NCT02165605).

Original languageEnglish (US)
JournalSupportive Care in Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hyaluronic Acid
Breast
Radiotherapy
Randomized Controlled Trials
Skin
Physicians
Patient Preference
Radiodermatitis
Placebos
Breast Neoplasms
Symptom Assessment
Controlled Clinical Trials
Radiation

Keywords

  • Breast cancer
  • Hyaluronan
  • Hyaluronic acid
  • Radiotherapy
  • Skin

ASJC Scopus subject areas

  • Oncology

Cite this

Novel hyaluronan formulation for preventing acute skin reactions in breast during radiotherapy : a randomized clinical trial. / Rahimi, Asal; Mohamad, Osama; Albuquerque, Kevin; Kim, D. W.Nathan; Chen, Diana; Thomas, Kimberly; Wooldridge, Rachel; Rivers, Aeisha; Leitch, Marilyn; Rao, Roshni; Haley, Barbara; Ahn, Chul; Garwood, Dan; Spangler, Ann.

In: Supportive Care in Cancer, 01.01.2019.

Research output: Contribution to journalArticle

@article{70d674d7d95c4438976c4c324631ee00,
title = "Novel hyaluronan formulation for preventing acute skin reactions in breast during radiotherapy: a randomized clinical trial",
abstract = "Purpose: We conducted a randomized, double-blind, vehicle-controlled clinical trial to investigate the use of a new proprietary hyaluronan (HA) formulation for the prevention of acute skin toxicity in breast cancer patients undergoing radiotherapy (RT). Methods: Thirty women with breast cancer undergoing whole breast RT were enrolled. Each patient was randomly assigned to HA formulation (study cream, S) on the medial or lateral half of the irradiated breast and the control cream (placebo, P) on the other half. The primary endpoint was physician’s evaluation of skin symptoms at week 5 during RT and week 2 post-RT. We also collected patients’ independent assessment of skin after RT, patient’s product preference, and an independent physician panel assessment of skin reactions based on photographs. Results: Twenty-eight patients were evaluable. On physician’s evaluation, there was no significant difference in radiation dermatitis between S and P and no overall preference to either cream at week 5 during or week 2 post-RT. More patients preferred S in evaluating skin appearance and skin reactions, but this did not reach statistical significance. Univariate analysis showed that physicians had an overall preference to the S cream at week 2 post-RT in patients with larger breasts. On the independent panel assessment, 3 reviewers saw no significant difference in radiation toxicity, whereas one reviewer reported better skin outcome with S cream at week 5. Conclusions: We found a nonstatistically significant patient preference but overall no significant radioprotective effects for this HA formulation compared with placebo except in patients with larger breasts. Trial registration: The study was registered at www.clinicaltrials.gov (NCT02165605).",
keywords = "Breast cancer, Hyaluronan, Hyaluronic acid, Radiotherapy, Skin",
author = "Asal Rahimi and Osama Mohamad and Kevin Albuquerque and Kim, {D. W.Nathan} and Diana Chen and Kimberly Thomas and Rachel Wooldridge and Aeisha Rivers and Marilyn Leitch and Roshni Rao and Barbara Haley and Chul Ahn and Dan Garwood and Ann Spangler",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00520-019-04957-0",
language = "English (US)",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Novel hyaluronan formulation for preventing acute skin reactions in breast during radiotherapy

T2 - a randomized clinical trial

AU - Rahimi, Asal

AU - Mohamad, Osama

AU - Albuquerque, Kevin

AU - Kim, D. W.Nathan

AU - Chen, Diana

AU - Thomas, Kimberly

AU - Wooldridge, Rachel

AU - Rivers, Aeisha

AU - Leitch, Marilyn

AU - Rao, Roshni

AU - Haley, Barbara

AU - Ahn, Chul

AU - Garwood, Dan

AU - Spangler, Ann

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: We conducted a randomized, double-blind, vehicle-controlled clinical trial to investigate the use of a new proprietary hyaluronan (HA) formulation for the prevention of acute skin toxicity in breast cancer patients undergoing radiotherapy (RT). Methods: Thirty women with breast cancer undergoing whole breast RT were enrolled. Each patient was randomly assigned to HA formulation (study cream, S) on the medial or lateral half of the irradiated breast and the control cream (placebo, P) on the other half. The primary endpoint was physician’s evaluation of skin symptoms at week 5 during RT and week 2 post-RT. We also collected patients’ independent assessment of skin after RT, patient’s product preference, and an independent physician panel assessment of skin reactions based on photographs. Results: Twenty-eight patients were evaluable. On physician’s evaluation, there was no significant difference in radiation dermatitis between S and P and no overall preference to either cream at week 5 during or week 2 post-RT. More patients preferred S in evaluating skin appearance and skin reactions, but this did not reach statistical significance. Univariate analysis showed that physicians had an overall preference to the S cream at week 2 post-RT in patients with larger breasts. On the independent panel assessment, 3 reviewers saw no significant difference in radiation toxicity, whereas one reviewer reported better skin outcome with S cream at week 5. Conclusions: We found a nonstatistically significant patient preference but overall no significant radioprotective effects for this HA formulation compared with placebo except in patients with larger breasts. Trial registration: The study was registered at www.clinicaltrials.gov (NCT02165605).

AB - Purpose: We conducted a randomized, double-blind, vehicle-controlled clinical trial to investigate the use of a new proprietary hyaluronan (HA) formulation for the prevention of acute skin toxicity in breast cancer patients undergoing radiotherapy (RT). Methods: Thirty women with breast cancer undergoing whole breast RT were enrolled. Each patient was randomly assigned to HA formulation (study cream, S) on the medial or lateral half of the irradiated breast and the control cream (placebo, P) on the other half. The primary endpoint was physician’s evaluation of skin symptoms at week 5 during RT and week 2 post-RT. We also collected patients’ independent assessment of skin after RT, patient’s product preference, and an independent physician panel assessment of skin reactions based on photographs. Results: Twenty-eight patients were evaluable. On physician’s evaluation, there was no significant difference in radiation dermatitis between S and P and no overall preference to either cream at week 5 during or week 2 post-RT. More patients preferred S in evaluating skin appearance and skin reactions, but this did not reach statistical significance. Univariate analysis showed that physicians had an overall preference to the S cream at week 2 post-RT in patients with larger breasts. On the independent panel assessment, 3 reviewers saw no significant difference in radiation toxicity, whereas one reviewer reported better skin outcome with S cream at week 5. Conclusions: We found a nonstatistically significant patient preference but overall no significant radioprotective effects for this HA formulation compared with placebo except in patients with larger breasts. Trial registration: The study was registered at www.clinicaltrials.gov (NCT02165605).

KW - Breast cancer

KW - Hyaluronan

KW - Hyaluronic acid

KW - Radiotherapy

KW - Skin

UR - http://www.scopus.com/inward/record.url?scp=85068850424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068850424&partnerID=8YFLogxK

U2 - 10.1007/s00520-019-04957-0

DO - 10.1007/s00520-019-04957-0

M3 - Article

C2 - 31273506

AN - SCOPUS:85068850424

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -